Summary: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as a promising cardiac safety platform, demonstrated by numerous validation studies using drugs with known cardiac adverse effects in humans. However, the challenge remains to implement hiPSC-CMs into cardiac de-risking of new chemical entities (NCEs) during preclinical drug development. Here, we used the calcium transient screening assay in hiPSC-CMs to develop a hazard score system for cardiac electrical liabilities. Tolerance interval calculations and evaluation of different classes of cardio-active drugs enabled us to develop a weighted scoring matrix. This approach allowed the translation of various pharmacological effects in hiPSC-CMs into a s...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
Cardiotoxicity is a major cause of attrition during (pre)clinical anticancer drug development [1] an...
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and ...
Introduction: Human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) preparations are ...
Cardiotoxicity is a severe side effect of drugs that induce structural or electrophysiological chang...
Cardiac safety assessment is challenging because a better understanding of torsadogenic mechanisms b...
Summary: To assess the utility of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-...
Introduction: Cardiac drug discovery are based in old methods that use animals, animal cells or modi...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high a...
Cardiovascular disease is still a major cause of ill-health and mortality, heart failure and arrhyth...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Cardiotoxicity is a major cause of attrition during (pre)clinical anticancer drug development [1] an...
The progress of medical technology and scientific advances in the field of anticancer treatment have...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
Cardiotoxicity is a major cause of attrition during (pre)clinical anticancer drug development [1] an...
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and ...
Introduction: Human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) preparations are ...
Cardiotoxicity is a severe side effect of drugs that induce structural or electrophysiological chang...
Cardiac safety assessment is challenging because a better understanding of torsadogenic mechanisms b...
Summary: To assess the utility of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-...
Introduction: Cardiac drug discovery are based in old methods that use animals, animal cells or modi...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high a...
Cardiovascular disease is still a major cause of ill-health and mortality, heart failure and arrhyth...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Cardiotoxicity is a major cause of attrition during (pre)clinical anticancer drug development [1] an...
The progress of medical technology and scientific advances in the field of anticancer treatment have...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
Cardiotoxicity is a major cause of attrition during (pre)clinical anticancer drug development [1] an...
More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and ...